SeaStar Medical, a medical technology company, went public via a SPAC merger with LMF Acquisition Opportunities, a blank cheque company, in a $85m deal. “We are excited to begin the next phase of our journey as a public company. This transaction provides us greater resources to advance our Selective Cytopheretic Device (SCD) for patients suffering from the devastating consequences of hyperinflammation. We have submitted our Humanitarian Device Exemption (HDE) application to the US Food and Drug Administration (FDA) for pediatric use, and we plan to launch a pivotal study of the SCD in adults with acute kidney injury (AKI) in the first quarter of 2023. As a public company, we will be better positioned to move these programs forward," Eric Schlorff, SeaStar Medical President and CEO.